← SynDRA
carfilzomib
SynDRA canonical compound SYN0041977 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | PSMB10 |
|---|
| Mechanism of action | Proteasome inhibitor |
|---|
| Indication | multiple myeloma |
|---|
| Disease area | hematologic malignancy |
|---|
All known targets
- PSMB9
- PSMB8
- PSMB5
- PSMB2
- PSMB10
- PSMB1
- PSMB7
- PSMA8
- PSMB6
- PSMB4
- PSMB3
- PSMB11
Mechanisms of action (all sources)
- proteasome inhibitor
- PSMD1 INHIBITOR
- PSMB2 INHIBITOR
- PSMB1 INHIBITOR
- PSMB5 INHIBITOR
- PSMB8 INHIBITOR
- PSMB9 INHIBITOR
- PSMB6 INHIBITOR
- PSMD14 INHIBITOR
- PSMA1 INHIBITOR
- PSMA2 INHIBITOR
- PSMA3 INHIBITOR
Drug classes
- Proteasome Inhibitors
- Proteasome Inhibitor
ATC classes
- L01X · OTHER ANTINEOPLASTIC AGENTS
Cross-references
Synonyms
- kyprolis
- PR 171
- NSC-758252
- PR-171
- Kyprolis
- Carfilzomib (PR-171)
- UNII-72X6E3J5AR
- 72X6E3J5AR
- CHEMBL451887
- CHEBI:65347
- NCGC00249613-01
- DSSTox_RID_82886
- DSSTox_CID_28616
- DSSTox_GSID_48690
- (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide
- N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide
- Carfilzomib (PR171)
- NSC 758252
- (2S)-4-methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide
- (alphaS)-alpha-[[2-(4-Morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-L-phenylalaninamide
- (2S)-N-((1S)-1-Benzyl-2-(((1S)-3-methyl-1-(((2R)-2-methyloxiran-2-yl)carbonyl)butyl)amino)-2-oxoethyl)-4-methyl-2-(((2S)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)amino)pentanamide
- (S)-4-Methyl-N-((S)-1-((S)-4-Methyl-1-((R)-2- Methyloxiran-2-yl)-1 -oxopentan-2-ylaMino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-MorpholinoacetaMido)-4-phenylbutanaMido)pentanaMide
- Carfilzomib [USAN]
- CAS-868540-17-4
- Carfilzomib [USAN:INN]
- MFCD11040997
- Kyprolis (TN)
- (2S)-N-[(1S)-1-Benzyl-2-[[(1S)-3-methyl-1-[[(2R)-2-methyloxiran-2-yl]carbonyl]butyl]amino]-2-oxoethyl]-4-methyl-2-[[(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide
- Carfilzomib; PR171
- CARFILZOMIB [MI]
- CARFILZOMIB [INN]
- CARFILZOMIB [JAN]
- CARFILZOMIB [VANDF]
- SCHEMBL85165
- CARFILZOMIB [WHO-DD]
- MLS006011102
- Carfilzomib (JAN/USAN/INN)
- GTPL7420
Reported adverse events
- Asthenia
- Back pain
- Chest pain
- Chills
- Constipation
- Cough
- Dizziness
- Fatigue
- Headache
- Hypertension
- Influenza
- Insomnia
Look up carfilzomib in the interactive SynDRA portal →